GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lipidor AB (FRA:L7R) » Definitions » EV-to-EBIT

Lipidor AB (FRA:L7R) EV-to-EBIT : -13.71 (As of May. 25, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Lipidor AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lipidor AB's Enterprise Value is €15.14 Mil. Lipidor AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.10 Mil. Therefore, Lipidor AB's EV-to-EBIT for today is -13.71.

The historical rank and industry rank for Lipidor AB's EV-to-EBIT or its related term are showing as below:

FRA:L7R' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.63   Med: -6.8   Max: 1.56
Current: -13.13

During the past 8 years, the highest EV-to-EBIT of Lipidor AB was 1.56. The lowest was -36.63. And the median was -6.80.

FRA:L7R's EV-to-EBIT is ranked worse than
100% of 692 companies
in the Drug Manufacturers industry
Industry Median: 16.645 vs FRA:L7R: -13.13

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Lipidor AB's Enterprise Value for the quarter that ended in Dec. 2024 was €2.20 Mil. Lipidor AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.10 Mil. Lipidor AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -50.11%.


Lipidor AB EV-to-EBIT Historical Data

The historical data trend for Lipidor AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipidor AB EV-to-EBIT Chart

Lipidor AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial -19.60 -8.85 -0.30 -1.30 -12.63

Lipidor AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.04 -1.30 -1.48 -0.95 -12.63

Competitive Comparison of Lipidor AB's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Lipidor AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipidor AB's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lipidor AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lipidor AB's EV-to-EBIT falls into.


;
;

Lipidor AB EV-to-EBIT Calculation

Lipidor AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15.139/-1.104
=-13.71

Lipidor AB's current Enterprise Value is €15.14 Mil.
Lipidor AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipidor AB  (FRA:L7R) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Lipidor AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-1.104/2.2029352
=-50.11 %

Lipidor AB's Enterprise Value for the quarter that ended in Dec. 2024 was €2.20 Mil.
Lipidor AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipidor AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Lipidor AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipidor AB Business Description

Traded in Other Exchanges
Address
c/o Ekonomistubben AB, Box 55931, Stockholm, SWE, 102 16
Lipidor AB is a pharmaceutical development company with a pipeline of drug development projects in the preclinical and clinical phases. The company develops drugs for the treatment of skin diseases such as psoriasis, bacterial skin infections, and atopic dermatitis.

Lipidor AB Headlines

No Headlines